Clinical pathway builder
Acute coronary syndrome — ED pathway
Version 3.2 · grounded in ESC 2024 + AHA/ACC 2025 + WHO PEN · adapted for Rwanda MoH district hospitals
Pathway canvas Trigger Action Decision Outcome
Evidence sources
- ESC 2024 ACS GuidelineClass I
- AHA/ACC 2025 NSTEMI Focused UpdateClass I
- WHO PEN protocol 5 — Africa adaptationStrong
- TIMI / GRACE 2.0 risk scoresValidated
Therapeutic comparison
| Antiplatelet | NNT MACE | NNH bleed |
|---|---|---|
| Ticagrelor | 53 | 143 |
| Prasugrel | 47 | 118 |
| Clopidogrel | 92 | 204 |
Patient-risk interpreter
GRACE 2.0 · 6-month mortality
12.4%
High risk · early invasive ≤24h recommended (Class I, ESC 2024)